#467: Combination Product Compliance: PMOA, 21 CFR Part 4 & QMS Alignment

Navigating the regulatory landscape for combination products requires understanding how primary modes of action (PMOA) dictate oversight pathways. In this episode, host Etienne Nichols sits down with Jim Fentress, Director of Regulatory Affairs at Galero (a Santa Group company), to unpack the structural differences and hidden pitfalls when medical device and pharmaceutical worlds collide. They discuss how the FDA handles lead agency designation across CDRH and CDER using interagency agreements and official Requests for Designation (RFD).

A central theme of the discussion is managing quality management systems under 21 CFR Part 4. The pair explore the friction that occurs when pharmaceutical companies act as lead applicants for drug-led combination products, requiring them to incorporate device design controls (ISO 13485 / QMSR) and CAPA systems into their existing CGMP framework. Jim explains the practical realities of integrating Part 210/211 elements—such as calculation of yield and stability testing—into a single, operational QMS without overcomplicating procedures.

Finally, the conversation delves into critical execution details: risk management under AAMI TIR105 (ISO 14971 vs. ICH Q9), labeling classifications (single entity, co-packaged, and cross-labeled), and strict change control protocols. Jim highlights how post-market design changes to a device constituent part can impact the pharmaceutical partner's NDA or baseline regulatory filings, underscoring the necessity of transparent cross-industry communication from initial development through full commercial release.

Key Timestamps

• 00:00 – Introduction to combination products and guest Jim Fentress.
• 00:48 – Understanding Primary Mode of Action (PMOA) and regulatory pathways (FDA vs. European authorities).
• 01:57 – FDA interagency agreements (CDRH and CDER) and Requests for Designation (RFD).
• 03:00 – 21 CFR Part 4 quality system integration (CGMP Part 210/211 and QMSR/Part 820).
• 05:22 – Navigating the communication gap between pharma companies and device manufacturers.
• 07:44 – Calculation of yield in drug manufacturing vs. medical device production.
• 09:05 – Risk management for combination products (AAMI TIR105: evaluating device-on-drug and drug-on-device risks).
• 12:15 – Bridging ISO 14971 and ICH Q9 framework structures in registration files.
• 13:16 – Design controls, user needs, and human factors validation (Module 5 / Section 3.2.R ECTD filings).
• 15:06 – Labeling pathways: Single Entity (Integral), Co-Packaged, and Cross-Labeled products.
• 18:18 – Change control risks: How minor device modifications affect drug application filings (NDAs, CBER/CDER supplements).
• 20:41 – Advice for device manufacturers partnering with pharma: Alignment on risk, documentation depth, and cleanroom requirements.

Standout Quotes

"There's four aspects of risk that you need to take into account: what is the risk of the drug alone, the risk of the delivery system alone, the risk of the drug on the device, and the risk of the device on the drug." — Jim Fentress

"Before you even think about making a change, you need to talk to your pharmaceutical partners because now what's represented as the co-packaged device constituent element is changing, and they need to inform the FDA." — Jim Fentress

Actionable Takeaways

• Establish Cross-Disciplinary Risk Management Early: Adopt frameworks like AAMI TIR105 to integrate traditional device risk protocols (ISO 14971) with pharmaceutical risk management (ICH Q9). Ensure assessment of cross-interaction hazards (e.g., drug interactions with delivery plastics, viscous drug effects on ejection times).
• Define Clear Part 4 QMS Interfaces: If operating primarily under device rules (QMSR/ISO 13485), build project-specific addenda to account for drug CGMP requirements such as stability testing, container-closure assessments, and calculation of yield limits.
• Align Post-Market Change Control Protocols: Establish explicit notification procedures between the device supplier and the NDA holder. Simple component material updates or geometry changes to a constituent part may require formal NDA supplements or changes-being-effected (CBE) filings with CDER.
• Scope Document Deliverables Upfront: Clarify whether the pharmaceutical partner requires high-level summary reports or the complete device master record (DMR) and design history file (DHF) to populate Section 3.2.R of their eCTD submission.
• Validate Cleanroom and Sterility Assumptions: Discuss cleanroom requirements early to avoid unnecessary cost structures; verify if an ISO 8 or ISO 7 environment is scientifically required for the assembly of non-sterile device constituents before adopting conservative pharma-grade aseptic norms (ISO 5).

Essential References

• 21 CFR Part 4: Regulation governing current good manufacturing practice (CGMP) requirements for combination products.
• AAMI TIR105: Technical Information Report providing guidance on the application of risk management to combination products.
• ICH Q9: International Council for Harmonisation guidelines for Quality Risk Management in pharmaceutical manufacturing.
• eCTD Section 3.2.R: Regional information section of the Electronic Common Technical Document where medical device constituent data is filed.
• Host Contact: Connect with Etienne Nichols on LinkedIn.

MedTech 101

Primary Mode of Action (PMOA)

The primary mode of action is the single mechanism that provides the primary therapeutic effect of a combination product.

Think of a drug-eluting stent:

• The main goal is to physically prop open a blocked artery (a mechanical action performed by the stent device).
• The drug baked into the metal coating slowly releases to prevent scar tissue from re-blocking the artery (an ancillary chemical action).

Because the physical propping open is the primary therapeutic mechanism, the FDA classifies the product as a device-led combination product under CDRH. Conversely, an epinephrine auto-injector's main therapeutic outcome comes from the epinephrine drug working in the bloodstream; the plastic casing and needle are auxiliary delivery mechanisms, making it a drug-led combination product overseen by CDER.

Feedback & Community

We want to hear from you! Have questions about combination product regulatory strategies, or want to suggest a topic for a future episode?

Email us directly at podcast@greenlight.guru. Every message is reviewed personally by our team to help shape upcoming content.

Sponsor Integration

This episode is sponsored by Greenlight Guru.

Navigating the blurred lines of 21 CFR Part 4 between drug CGMPs and device design controls requires dynamic, interconnected quality tools. Greenlight Guru provides purpose-built Quality Management Software (QMS) and Electronic Data Capture (EDC) solutions designed specifically for MedTech teams. Whether you are managing complex design controls, tracking supplier changes, or managing clinical trial data for combination products, Greenlight Guru helps you bring safe, compliant devices to market faster.

Discover how to streamline your regulatory files and risk matrix at www.greenlight.guru.